Sean Duffy Sells 8,628 Shares of Omada Health (NASDAQ:OMDA) Stock

Omada Health, Inc. (NASDAQ:OMDA) CEO Sean Duffy sold 8,628 shares of the business’s stock in a transaction on Friday, August 7th. The shares were sold at an average price of $21.85, for a total transaction of $188,521.80. Following the sale, the chief executive officer owned 411,861 shares of the company’s stock, valued at approximately $8,999,162.85. This represents a 2.05% decrease in their ownership of the stock. The sale was disclosed in a legal filing with the SEC, which is available at this link.

Omada Health Price Performance

OMDA stock opened at $23.84 on Thursday. The company has a market cap of $1.46 billion, a P/E ratio of 476.80 and a beta of 1.73. Omada Health, Inc. has a 1 year low of $10.28 and a 1 year high of $26.92. The stock’s fifty day moving average price is $20.74 and its 200-day moving average price is $16.38.

Omada Health (NASDAQ:OMDA) last announced its earnings results on Thursday, August 6th. The company reported $0.08 earnings per share (EPS) for the quarter, topping the consensus estimate of ($0.02) by $0.10. The business had revenue of $87.83 million for the quarter, compared to analysts’ expectations of $80.93 million. Omada Health had a return on equity of 2.67% and a net margin of 1.39%. As a group, analysts expect that Omada Health, Inc. will post -0.01 earnings per share for the current year.

Key Stories Impacting Omada Health

Here are the key news stories impacting Omada Health this week:

• Positive Sentiment: Q2 results showed improving profitability and growth. Omada reported earnings of $0.08 per share versus the consensus estimate of a $0.02 loss, while revenue of approximately $87.8 million exceeded expectations of $80.9 million. The results suggest that the company’s digital chronic-care business is converting revenue growth into earnings. Omada Health: Q2 Shows More Evidence Of Growth Converting Into Earnings
• Positive Sentiment: Analyst price targets continue to rise. Robert W. Baird lifted its target from $15 to $25 while maintaining a neutral rating. Other recent targets include $27 from Citizens JMP and $35 from BTIG, contributing to a consensus “Moderate Buy” rating and an average target of $25.67.
• Neutral Sentiment: Baird’s neutral rating signals valuation concerns. Although the higher target implies additional upside, the firm’s hold-equivalent rating suggests that much of Omada’s improved earnings outlook may already be reflected in the stock’s valuation.
• Negative Sentiment: Multiple senior executives sold shares. CEO Sean Duffy sold a combined 21,570 shares, CFO Steven Cook sold 16,842 shares, President Wei-Li Shao sold 8,866 shares, and Chief Accounting Officer Craig Gracey sold 1,042 shares. The transactions totaled roughly $1.16 million and occurred at prices near $25. While insider sales may reflect personal or equity-compensation planning, the concentration of selling can weigh on sentiment because it reduces management ownership.

Analyst Ratings Changes

Several research analysts have recently weighed in on OMDA shares. Barclays lifted their price target on shares of Omada Health from $20.00 to $25.00 and gave the stock an “overweight” rating in a research note on Monday, August 3rd. Morgan Stanley reaffirmed an “overweight” rating and issued a $30.00 target price on shares of Omada Health in a report on Monday, June 22nd. Citizens Jmp lifted their target price on Omada Health from $21.00 to $27.00 and gave the company a “market outperform” rating in a research report on Monday, July 20th. Needham & Company LLC reissued a “buy” rating and set a $28.00 price target on shares of Omada Health in a report on Friday, May 8th. Finally, Robert W. Baird upped their price target on Omada Health from $15.00 to $25.00 and gave the stock a “neutral” rating in a research report on Wednesday. Eleven investment analysts have rated the stock with a Buy rating, two have given a Hold rating and one has given a Sell rating to the stock. Based on data from MarketBeat, the stock currently has a consensus rating of “Moderate Buy” and an average price target of $25.75.

Institutional Trading of Omada Health

A number of hedge funds and other institutional investors have recently modified their holdings of OMDA. Quarry LP purchased a new stake in Omada Health in the 4th quarter worth $29,000. TD Waterhouse Canada Inc. purchased a new stake in shares of Omada Health during the 4th quarter worth approximately $32,000. Raymond James Financial Inc. bought a new position in Omada Health during the second quarter valued at $32,000. Inlight Wealth Management LLC purchased a new position in Omada Health in the fourth quarter worth about $45,000. Finally, Versant Capital Management Inc boosted its holdings in shares of Omada Health by 319.3% in the 2nd quarter. Versant Capital Management Inc now owns 2,998 shares of the company’s stock worth $66,000 after purchasing an additional 2,283 shares during the period.

Omada Health Company Profile

Omada Health is a digital health company that specializes in the prevention and management of chronic conditions through personalized, technology-driven programs. The company’s platform combines data analytics, behavioral science and human coaching to support individuals at risk for or living with conditions such as prediabetes, type 2 diabetes, hypertension and musculoskeletal disorders. Participants access the program via a mobile app or web portal, where they receive tailored curriculum, feedback on health metrics and ongoing virtual coaching.

In addition to its core disease-management offerings, Omada Health has expanded its services to include mental health support and digital therapeutics for weight management.